CONGENITAL MYASTHENIC SYNDROMES

Congenital Myasthenic Syndromes — genetic neuromuscular junction disorders where the standard treatment for autoimmune myasthenia gravis can make certain subtypes dramatically worse, and only molecular diagnosis distinguishes them.

Whole genome sequencing evaluates all 30+ CMS genes — CHRNE, DOK7, RAPSN, COLQ, AGRN, SCN4A, and others — providing the gene-specific diagnosis that determines whether pyridostigmine, salbutamol, 3,4-DAP, or fluoxetine is the correct treatment.

CHRNE
DOK7
RAPSN
COLQ
AGRN
SCN4A

About this condition

Congenital Myasthenic Syndromes

Congenital myasthenic syndromes (CMS) are a genetically heterogeneous group of inherited disorders of neuromuscular junction (NMJ) transmission caused by pathogenic variants in over 30 genes encoding presynaptic, synaptic cleft, and postsynaptic NMJ proteins. Unlike autoimmune myasthenia gravis (MG), which is caused by antibodies against acetylcholine receptors (AChR) or muscle-specific kinase (MuSK), CMS is genetic and present from birth or early childhood. CMS affects approximately 1 in 100,000 and is frequently misdiagnosed as seronegative autoimmune MG.

CMS subtypes are classified by the location of the NMJ defect: presynaptic (CHAT, SYT2), synaptic (COLQ, LAMB2), and postsynaptic (CHRNE, RAPSN, DOK7, AGRN, SCN4A). The most critical clinical distinction is that DOK7-CMS and COLQ-CMS are worsened by acetylcholinesterase inhibitors (pyridostigmine/Mestinon) — the standard first-line treatment for autoimmune MG. Administering pyridostigmine to a DOK7 or COLQ patient based on an incorrect MG diagnosis produces clinical deterioration rather than improvement. Salbutamol (a β2-agonist) is the treatment of choice for DOK7-CMS.

Gene-specific CMS treatment represents one of the clearest examples of pharmacogenomic medicine in neurology: CHRNE (the most common CMS gene) responds to pyridostigmine and 3,4-DAP. RAPSN responds to pyridostigmine and salbutamol. DOK7 requires salbutamol and is worsened by pyridostigmine. COLQ requires ephedrine or salbutamol and is worsened by pyridostigmine. Slow-channel CMS (gain-of-function AChR variants) responds to fluoxetine or quinidine. Without molecular diagnosis, treatment is empirical — and the wrong empirical choice can cause life-threatening respiratory crisis.

DOK7-CMS and COLQ-CMS are actively WORSENED by pyridostigmine — the standard first-line myasthenia treatment. Misdiagnosis as autoimmune MG and treatment with pyridostigmine can cause respiratory failure in these patients.

Gene locus: CHRNE (17p13.2), DOK7 (4p16.3), RAPSN (11p11.2), COLQ (3p25.1), AGRN (1p36.33), SCN4A (17q23.3)

CMS treatment is entirely gene-specific — one gene's cure is another gene's poison. Molecular diagnosis is not optional; it is the difference between the right drug and the wrong drug.

The wrong treatment causes respiratory crisis — DOK7 patients given pyridostigmine deteriorate rather than improve

DOK7-CMS produces NMJ failure through impaired agrin-MuSK signaling and endplate remodeling. Pyridostigmine, by increasing acetylcholine concentration at an already dysfunctional endplate, exacerbates the NMJ pathology. Multiple case reports document respiratory decompensation in DOK7 patients treated with pyridostigmine based on an incorrect autoimmune MG diagnosis. Molecular DOK7 diagnosis triggers immediate pyridostigmine discontinuation and initiation of salbutamol — producing dramatic clinical improvement. This gene-specific treatment reversal is only possible with molecular diagnosis.

CMS is present from birth but frequently misdiagnosed for years — neonatal hypotonia, feeding difficulty, and ptosis should trigger NMJ evaluation

CMS typically presents in infancy with hypotonia, poor feeding, ptosis, and fatigable weakness — features that overlap with many other neonatal conditions. The diagnosis is frequently delayed for years because infant weakness is attributed to 'floppy baby syndrome,' cerebral palsy, or congenital myopathy. AChR antibody testing is negative (because CMS is not autoimmune), and the patient may be labeled as 'seronegative MG' without receiving genetic testing. WGS performed for unexplained neonatal or infantile weakness evaluates all CMS genes alongside other neuromuscular genes, identifying the treatable NMJ defect.

Congenital Myasthenic Syndromes — genetic neuromuscular junction disorders where the standard treatment for autoimmune myasthenia gravis can make certain subtypes dramatically worse, and only molecular diagnosis distinguishes them.

Congenital Myasthenic Syndromes

CMS treatment is entirely gene-specific — one gene's cure is another gene's poison. Molecular diagnosis is not optional; it is the difference between the right drug and the wrong drug.

The wrong treatment causes respiratory crisis — DOK7 patients given pyridostigmine deteriorate rather than improve

CMS is present from birth but frequently misdiagnosed for years — neonatal hypotonia, feeding difficulty, and ptosis should trigger NMJ evaluation

Others in Neurological

One test. A lifetime of answers.